Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxycodone/naloxone prolonged release versus placebo for idiopathic restless legs syndrome with daytime symptoms
2009-011107-23Phase 3Completed
- Sponsor
- Mundipharma Research
- Start
- Dec 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in restless legs syndrome (RLS) comparing oxycodone/naloxone prolonged release with placebo (2 arms). Primary endpoint: Change in IRLS total score. Started Dec 2009; status: completed.
02
Drugs
oxycodonenaloxone
03
Conditions
restless legs syndrome (RLS)
Beyond the preview
Go deeper on 2009-011107-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011107-23.